肝切除对比全身治疗用于肝局限性BRAF V600E突变结直肠癌肝转移:多中心回顾性研究
这项国际多中心回顾性研究纳入170例肝局限性BRAF V600E突变结直肠癌肝转移患者,比较肝切除(119例)与单纯全身治疗(51例)的预后。手术组复发多局限于单一部位,全身治疗组弥漫性进展更常见(19% vs 44%,P=0.002);手术组中位总生存更长(35 vs 20个月,P<0.001),多因素分析显示肝切除与更好总生存独立相关(HR 0.37,95%CI 0.21-0.65),倾向评分匹配队列结果一致。
要点
- BRAF V600E突变不应视为可切除肝局限性结直肠癌肝转移的手术禁忌。
- 肝切除组中位总生存35个月,优于单纯全身治疗的20个月。
- 倾向评分匹配后肝切除仍与更好总生存独立相关(HR 0.47)。
核心结论
- 对于可切除的肝局限性BRAF V600E突变结直肠癌肝转移,肝切除不应因BRAF V600E突变而被视为禁忌。
研究设计与样本
- 国际多中心观察性回顾性研究,从机构数据库纳入170例肝局限性BRAF V600E突变结直肠癌肝转移患者,其中119例接受肝切除、51例接受单纯全身治疗。
- 采用全队列多因素分析和倾向评分匹配队列比较复发/进展模式与总生存。
主要发现
- 手术组复发多局限于单一部位,全身治疗组弥漫性进展更常见(19% vs 44%,P=0.002)。
- 手术组中位总生存35个月,全身治疗组20个月(P<0.001)。
- 全队列多因素分析显示肝切除与更好总生存独立相关(HR 0.37,95%CI 0.21-0.65)。
- 倾向评分匹配队列中手术组中位总生存28个月,全身治疗组20个月(P<0.001),肝切除与更好总生存独立相关(HR 0.47,95%CI 0.25-0.88)。
临床怎么用
- 对可切除的肝局限性BRAF V600E突变结直肠癌肝转移患者,应与多学科团队讨论肝切除,不应仅因BRAF V600E突变而排除手术。
- 术前评估需确认肝转移限于肝脏且可切除,并结合全身治疗策略个体化决策。
局限性
- 本研究为回顾性观察性设计,存在选择偏倚可能。
- 样本量有限(共170例),结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, only two studies have compared the outcomes of patients with liver-limited BRAF V600E-mutated colorectal liver metastases (CRLMs) managed with resection versus systemic therapy alone, and these have reported contradictory findings. METHODS: In this observational, international, multicentre study, patients with liver-limited BRAF V600E-mutated CRLMs treated with resection or systemic therapy alone were identified from institutional databases. Patterns of recurrence/progression and overall survival were compared using multivariable analyses of the entire cohort and a propensity score-matched cohort. RESULTS: Of 170 patients included, 119 underwent hepatectomy and 51 received systemic treatment. Surgically treated patients had a more favourable pattern of recurrence with most recurrences limited to a single site, whereas diffuse progression was more common among patients who received systemic treatment (19 versus 44%; P = 0.002). Surgically treated patients had longer median overall survival (35 versus 20 months; P < 0.001). Hepatectomy was independently associated with better OS than systemic treatment alone (HR 0.37, 95% c.i. 0.21 to 0.65). In the propensity score-matched cohort, surgically treated patients had longer median overall survival (28 versus 20 months; P < 0.001); hepatectomy was independently associated with better overall survival (HR 0.47, 0.25 to 0.88). CONCLUSION: BRAF V600E mutation should not be considered a contraindication to surgery for patients with resectable, liver-only CRLMs.
引用
- Margonis GA, Wang JJ, Boerner T, et al. Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study. Br J Surg. 2024. PMID: 39051667. doi:10.1093/bjs/znae176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。